Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Want to see ZVRA full AI Analyst Report?
Total Valuation
Zevra Therapeutics has a market cap or net worth of $620.12M. The enterprise value is $498.48M.
Market Cap$620.12M
Enterprise Value$498.48M
Share Statistics
Zevra Therapeutics has 59,115,086 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,115,086
Owned by Insiders1.44%
Owned by Institutions26.78%
Financial Efficiency
Zevra Therapeutics’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -1.65%.
Return on Equity (ROE)0.54
Return on Assets (ROA)0.29
Return on Invested Capital (ROIC)-1.65%
Return on Capital Employed (ROCE)-0.02
Revenue Per Employee1.80M
Profits Per Employee1.41M
Employee Count59
Asset Turnover0.37
Inventory Turnover9.47
Valuation Ratios
The current PE Ratio of Zevra Therapeutics is 3.6. Zevra Therapeutics’s PEG ratio is -0.04.
PE Ratio3.6
PS Ratio4.65
PB Ratio3.20
Price to Fair Value3.20
Price to FCF-203.69
Price to Operating Cash Flow45.89
PEG Ratio-0.04
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 106.47M and earned 83.23M in profits. Earnings per share was 1.40.
Revenue106.47M
Gross Profit89.99M
Operating Income-4.23M
Pretax Income86.68M
Net Income83.23M
EBITDA98.71M
Earnings Per Share (EPS)1.40
Cash Flow
In the last 12 months, operating cash flow was 12.77M and capital expenditures -771.00K, giving a free cash flow of 11.99M billion.
Operating Cash Flow12.77M
Free Cash Flow11.99M
Free Cash Flow per Share0.20
Dividends & Yields
Zevra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change15.95%
50-Day Moving Average10.05
200-Day Moving Average9.40
Relative Strength Index (RSI)45.02
Average Volume (3m)2.44M
Important Dates
Zevra Therapeutics upcoming earnings date is Aug 18, 2026, After Close (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Zevra Therapeutics as a current ratio of 5.68, with Debt / Equity ratio of 0.56%
Current Ratio5.68
Quick Ratio5.63
Debt to Market Cap0.12
Net Debt to EBITDA<0.01
Interest Coverage Ratio-0.53
Taxes
In the past 12 months, Zevra Therapeutics has paid 3.45M in taxes.
Income Tax3.45M
Effective Tax Rate0.04
Enterprise Valuation
Zevra Therapeutics EV to EBITDA ratio is 5.03, with an EV/FCF ratio of -204.02.
EV to Sales4.66
EV to EBITDA5.03
EV to Free Cash Flow-204.02
EV to Operating Cash Flow-310.63
Balance Sheet
Zevra Therapeutics has $95.59M in cash and marketable securities with $1.15M in debt, giving a net cash position of $94.45M billion.
Cash & Marketable Securities$95.59M
Total Debt$1.15M
Net Cash$94.45M
Net Cash Per Share$1.60
Tangible Book Value Per Share$2.60
Margins
Gross margin is 85.51%, with operating margin of -3.98%, and net profit margin of 78.17%.
Gross Margin85.51%
Operating Margin-3.98%
Pretax Margin81.41%
Net Profit Margin78.17%
EBITDA Margin92.71%
EBIT Margin88.90%
Analyst Forecast
The average price target for Zevra Therapeutics is $24.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$24.00
Price Target Upside124.93% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast201.29%
EPS Growth Forecast―